Rubius Therapeutics to Host Investor Webcast to Discuss Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Patients with Advanced Solid Tumors on April 8, 2022, at 1:15 PM ET
April 07 2022 - 8:00AM
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage
biopharmaceutical company that is biologically engineering red
blood cells to create an entirely new class of cellular medicines
called Red Cell Therapeutics™ for the treatment of cancer and
autoimmune diseases, today announced the details of its webcast to
discuss updated clinical data from the ongoing monotherapy Phase 1
arm of the Phase 1/2 clinical trial of RTX-240 in patients with
advanced solid tumors and relapsed/refractory acute myeloid
leukemia on April 8, 2022, at 1:15 p.m. ET.
In addition to members of the Rubius management team, Alexander
I. Spira, M.D., Ph.D., FACP, Co-Director, Virginia Cancer
Specialists Research Institute, Director, Thoracic and Phase 1
Program and RTX-240 clinical investigator, will join the webcast to
discuss the evolving oncology therapeutics landscape and clinical
development opportunities for RTX-240.
The audio webcast will be available on the Events and
Presentations page within the Investors and Media section of the
Rubius Therapeutics website. The update may also be accessed by
dialing (800) 289-0045 (domestic) or (615) 622-8086 (international)
five minutes prior to the start of the call. The conference ID is
7865329. An archived webcast will be accessible for 90 days after
the event.
About Rubius TherapeuticsRubius Therapeutics is
a clinical-stage biopharmaceutical company developing a new class
of medicines called Red Cell Therapeutics™. The Company’s
proprietary RED PLATFORM® was designed to biologically engineer and
culture Red Cell Therapeutics™ that are selective, potent and
off-the-shelf allogeneic cellular therapies for the potential
treatment of several diseases across multiple therapeutic areas.
Rubius’ initial focus is to advance RCT™ product candidates for the
treatment of cancer and autoimmune diseases by leveraging two
distinct therapeutic modalities — potent cell-cell interaction and
tolerance induction. Rubius Therapeutics was recently named
among the 2021 Top Places to Work in Massachusetts by the Boston
Globe, and its manufacturing site was recently
named 2021 Best Places to Work in Rhode Island by
Providence Business News. For more information, visit
www.rubiustx.com, follow us on Twitter or LinkedIn or like us on
Facebook.
Contacts: InvestorsLori
Murray, Chief Corporate Affairs Officerlori.murray@rubiustx.com
Media Marissa Hanify, Director, Corporate
Communicationsmarissa.hanify@rubiustx.com
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rubius Therapeutics (NASDAQ:RUBY)
Historical Stock Chart
From Apr 2023 to Apr 2024